Kevin Kalinsky, MD, MS, FASCO (@KalinskyKevin) ranks #17 among US breast cancer KOLs on X in 2026, by engagement from fellow physicians. 11 physicians shared, quoted or replied to their posts this year. CMS Open Payments lists $18,311 in 2025 general payments.
At a Glance
- Breast Cancer: US #17 · 11 physicians engaged
- Presented at ESMO 2026, ASCO 2026 in 2026
- CMS Open Payments lists $18,311 in 2025 general payments.
This Month
What Kevin Kalinsky, MD, MS, FASCO has posted in the last 30 days. Updated November 10, 2026.
No trial posts in the last 30 days.
Next meeting to watch: SABCS 2026 · San Antonio · Dec 8–11, 2026
2026 Rankings
| List | US rank | Global rank | Physicians engaged | Physician engagements | |
|---|---|---|---|---|---|
| Breast Cancer | #17 | — | 11 | 13 | Full ranking |
From the Podium, 2025–26
Talks, posters and sessions Kevin Kalinsky, MD, MS, FASCO presented at SABCS 2025 and 2026 meetings, each confirmed by a public source.
- ESMO 2026 · Rapid oral (1RO)Final overall survival analysis of postMONARCH: abemaciclib plus fulvestrant after progression on prior CDK4/6 inhibitor in HR+, HER2- advanced breast cancer
- ASCO 2026 · PresentationProgression-free survival after next line of treatment and subsequent therapies in the ASCENT-04 study of previously untreated PD-L1+ mTNBC treated with sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembrolizumab
What Colleagues Are Saying About Kevin Kalinsky, MD, MS, FASCO
2026 posts by fellow physicians that mention @KalinskyKevin, quoted word for word.
After a comprehensive review of molecular platforms in early breast cancer, amazing @KalinskyKevin shares their institutional approach 👏👏👏 @myESMO #ESMO26 https://t.co/68bg7Z5Xd1
Phase III postMONARCH: Final OS Analysis #ESMO26 @KalinskyKevin Abemaciclib + fulvestrant numerically improved OS after CDK4/6i (32.1 vs 24.6 months; HR 0.80, P=0.11), without statistical significance. PFS (HR 0.78), PFS2 (HR 0.76), and time to chemotherapy (HR 0.76) favored abemaciclib.
At #ESMO26 rapid oral session on advanced #breastcancer @KalinskyKevin presents results from postMONARCH Abema + fulvestrant showed numeric, non significant ⬆️ OS in aBC after PD to CDK4-6i Modest PFS improvement @OncoAlert
📌 Progression-free survival after next line of treatment and subsequent therapies in the ASCENT-04 study of participants with previously untreated PD-L1+ mTNBC treated with sacituzumab govitecan plus pembrolizumab vs chemotherapy plus pembro. @KalinskyKevin 🎙️✨ #ASCO26 @OncoAlert #OncoAlertAF 👉🏻 PFS2 was longer in the SG + pembro group compared with the chemo + pembro group despite the high rate of crossover in the chemo + pembro group, with a 33% reduction in risk of a PF2 event with SG + pembro
Six years into NATALEE, the key question is no longer whether adjuvant ribociclib improves iDFS. Does the benefit remain durable-and is an OS signal emerging? LBA25 at #ESMO26, led by Dennis J. Slamon, with investigators @KalinskyKevin @LoiSher. What would change your practice most: absolute iDFS gain, OS maturity, or long-term treatment burden? #bcsm
Industry Payments
CMS Open Payments · 2025 general payments
$18,311 across 27 payments